{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Includes both complete responses (CR) and partial responses (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions: Complete Response (CR) is defined as the disappearance of all target lesions (any pathological lymph nodes must have reduction in short axis to \\<10 mm); Partial Response (PR) is defined as \\>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Overall Response (OR) = CR + PR.","groups":[{"description":"Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.\n\nafatinib dimaleate: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Afatinib)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis population includes those patients in the main Phase II study","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Overall Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}